Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Syndax Pharmaceuticals, Inc. (SNDX : NSDQ)
 
 • Company Description   
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Number of Employees: 298

 
 • Price / Volume Information   
Yesterday's Closing Price: $19.94 Daily Weekly Monthly
20 Day Moving Average: 1,783,980 shares
Shares Outstanding: 88.61 (millions)
Market Capitalization: $1,766.88 (millions)
Beta: 0.41
52 Week High: $25.59
52 Week Low: $8.59
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.05% -9.69%
12 Week -3.53% -10.82%
Year To Date -5.09% -13.49%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
730 Third Avenue 9th Floor
-
New York,NY 10017
USA		 ph: 781-419-1400
fax: 781-419-1420		 ir@syndax.com http://www.syndax.com
 
 • General Corporate Information   
Officers
Michael A. Metzger - Chief Executive Officer and Director
Dennis G. Podlesak - Chairman
Keith A. Goldan - Chief Financial Officer
Martin H. Huber - Director
Jennifer Jarrett - Director

Peer Information
Syndax Pharmaceuticals, Inc. (CORR.)
Syndax Pharmaceuticals, Inc. (RSPI)
Syndax Pharmaceuticals, Inc. (CGXP)
Syndax Pharmaceuticals, Inc. (BGEN)
Syndax Pharmaceuticals, Inc. (GTBP)
Syndax Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87164F105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/03/26
Share - Related Items
Shares Outstanding: 88.61
Most Recent Split Date: (:1)
Beta: 0.41
Market Capitalization: $1,766.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.45 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.66 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 27.94% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 42.45
Price/Cash Flow: -
Price / Sales: 8.13
EPS Growth
vs. Year Ago Period: 51.02%
vs. Previous Quarter: 38.46%
Sales Growth
vs. Year Ago Period: 223.64%
vs. Previous Quarter: -5.62%
ROE
03/31/26 - -256.65
12/31/25 - -206.62
09/30/25 - -160.60
ROA
03/31/26 - -45.25
12/31/25 - -49.25
09/30/25 - -49.58
Current Ratio
03/31/26 - 5.47
12/31/25 - 4.40
09/30/25 - 4.64
Quick Ratio
03/31/26 - 5.06
12/31/25 - 4.12
09/30/25 - 4.42
Operating Margin
03/31/26 - -111.88
12/31/25 - -165.37
09/30/25 - -279.31
Net Margin
03/31/26 - -111.88
12/31/25 - -165.37
09/30/25 - -279.31
Pre-Tax Margin
03/31/26 - -111.88
12/31/25 - -165.60
09/30/25 - -279.31
Book Value
03/31/26 - 0.47
12/31/25 - 0.74
09/30/25 - 1.34
Inventory Turnover
03/31/26 - 0.32
12/31/25 - 0.35
09/30/25 - 0.43
Debt-to-Equity
03/31/26 - 8.26
12/31/25 - 5.32
09/30/25 - 2.78
Debt-to-Capital
03/31/26 - 89.21
12/31/25 - 84.18
09/30/25 - 73.55
 

Powered by Zacks Investment Research ©